Nov. 9, 2022 – Researchers have long known that racial and ethnic minorities are less likely to be prescribed lifesaving addiction treatment options than white people.
But even when Black and Hispanic patients start a prescription for buprenorphine — the most popular medication to help those in recovery fight cravings — the typical duration of their treatment is shorter than that of white patients, according to a new data analysis published Wednesday in JAMA Psychiatry.
The analysis, which sorted through 15 years of prescription data by race and ethnicity, also revealed that the percentage of minority patients who remained on buprenorphine for more than 180 days — the minimum recommended duration — was significantly below that of white patients.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…